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Abstract
BACKGROUND: SARS-CoV-2 outbreaks remains a medical and economic challenge, due to the lack of a suitable 
drug or vaccine. The glycan in some proteins plays an important role in protein folding, sorting, transport, and 
oligomerization, so the hindering of N-linked glycosylation of glycoproteins will prevent assembly of the virion. 
Tunicamycin anticancer drug inhibits the N- linked glycan.
AIM: This study aimed to find out the mechanism action of tunicamycin on the viral glycoproteins. 
RESULTS: The growth of the virus in the presence of tunicamycin conducted in the production of non-infectious 
and absence of spike protein (spikeless virions). Tunicamycin inhibits E2, S, and M glycoproteins of coronaviruses. 
Tunicamycin has also diminished glycosylation of PTMs such as HE, and 8ab of SARS-CoV. Finally,
CONCLUSION: This study recommends using this drug to treat the SARS-CoV-2.
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Introduction
Since the last December, a new coronavirus 
has been a challenge for all of the world. The reason 
of elevation number of infections and fatality that the 
researchers failed to find suitable drug or vaccine 
to stem the outbreaks [1]. A few studies focused on 
the effect of N- and O-glycosylation through the 
process of virion assembly. N-linked glycosylation 
is the attachment of an oligosaccharide (glycan), 
to a nitrogen atom an asparagine (Asn) residue of a 
protein. This linkage is important for the structure and 
function of some eukaryotic proteins. Severe acute 
respiratory syndrome coronavirus (SARS-CoV) is one 
of viruses that contain N-linked glycoproteins which are 
glycosylated by the transfer of core oligosaccharides 
from a dolichol pyrophosphate carrier to asparagine 
residues on the polypeptide [2]. O-linked glycosylation 
is the attachment of a sugar molecule to the oxygen 
atom on serine (Ser) or threonine (Thr) residues 
in a protein. O-glycosylation is a post-translational 
modification (PTM) that occurs after the protein has 
been synthesized. It occurs either in the endoplasmic 
reticulum or Golgi apparatus and it influences on 
the stability and regulation of protein [3]. The main 
function of O-glycan is allowing recognition of foreign 
material and controlling cell metabolism. The changes 
in O-glycosylation are important in many diseases 
including cancer, diabetes Alzheimer’s, as well as 
some viral infections [4]. Because glycosylation and 
transport of viral proteins depend on cellular processes, 
prevention this process depends on the type of the 
viral protein and the activity of the substrate to diminish 
it. Coronavirus glycoproteins may be glycosylated 
by a different mechanism. This glycoproteins serve 
as a useful model for the study of N- and O-linked 
glycoproteins [5].
The Role of Tunicamycin (TM)
TM, an antibiotic, was produced by 
Streptomyces clavuligerus and Streptomyces 
lysosuperficus bacteria along with several other 
species and a proposed biosynthetic pathway was 
characterized. TM is a white crystalline powder which 
is soluble in alkaline water, pyridine, and hot methanol, 
slightly soluble in ethanol and n-butanol and insoluble 
in acetone, ethyl acetate, chloroform, benzene, and 
acidic water [6].
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TM, Figure 1, is an analog of UDP-N-
acetylglucosamine, interfered with the formation of 
dolichol pyrophosphate-acetylglucosamine which acts as 
a carrier for N-glycosidic linkage of core oligosaccharides 
to asparagine (Asn) residues on glycoproteins. The 
bacteria utilize the enzymes in the tun gene cluster 
(TunA-N) to make TMs. Several of cellular glycoproteins 
contain glycosylation linkage such as immunoglobulins, 
fetuin, thyroglobulin, and proteoglycan. Tunicamycin 
inhibits the first step in the biosynthesis of N-glycosylation 
linked in the ER resulting produced many misfolded 
proteins [7]. When the antibiotic blocks glycosylation 
of N-glycans, the cell cycle arrests at the G1 phase in 
human cells. The previous studies suggested that TM 
may work as a therapeutic drug against cancer cells as it 
has been shown to sensitize human colon and prostate 
cancer cells to TRAIL-induced apoptosis. The inhibited 
glycosylation of the structural glycoproteins was showed 
in alphaviruses, bunyaviruses, herpesviruses, and 
myxoviruses and all other viruses possess glycoprotein 
envelopes. Han et al. proposed that inhibition of the 
N-linked glycan biosynthesis by TM may be a promising 
therapeutic strategy for enhancing the sensitivity of 
cancer cells to trastuzumab [8].
Mechanism of Action of TM
TM inhibits the reverse reactions in 
the first step of the biosynthesis of N-linked 
oligosaccharides in cells. It prevents the 
formation of UDP-N-acetylglucosamine from 
N-acetylglucosaminylpyrophosphoryl dolichol. The 
inhibition is increased by pre-incubating the enzyme 
with antibiotic for up to 5 min before addition the 
substrate. The addition of phosphatidylcholine at 
the concentration up to 20 mM does not affect the 
inhibition regardless of whether it was added during 
the pre-incubation or at the same time at the substrate. 
TM binds to the heat denatured microsomal particles 
of aorta as shown by the fact that pre-incubation 
of the antibiotic with these particles prevented the 
inhibition of the N-acetylglucosamin-1-phosphate 
transferase [9].
The Glycosylation of E1 and E2 
Glycoproteins of Coronavirus
The transmembrane glycoprotein El composed 
of three domains: A glycosylated domain projects 
from the envelope. The second domain lies within the 
membrane, and the third domain interacts with the 
nucleocapsid inside the viral envelope. El may be an 
O-linked glycoprotein [10]. Glycosylation of El appears 
post-translational event. The glycoprotein E2 forms 
the large petal-shaped peplomers characteristic of the 
coronavirus envelope. E2 is a 180 kDa which can be 
cleaved by trypsin to yield two 90 kDa components. 
It has been recorded that TM inhibits formation of 
the E2 glycoprotein but does not prevent synthesis 
or glycosylation of the glycoprotein El through the 
formation or releasing of virion from the infected cell. 
Moreover, the shift from the non-glycosylated 20 kDa 
form to the glycosylated 23 kDa form does not inhibit 
by TM [11], [12]. This provides indirect evidence that 
E1 is not an N-linked glycoprotein but may be an 
O-linked glycoprotein. Although El glycoproteins are 
more negatively charged than those of E2, these 
glycoproteins differ in carbohydrate composition, 
electrophoretic patterns of glycopeptides, and response 
to the antibiotic [13]. These data suggested that E1 
is an O-linked glycoprotein while E2 is an N-linked 
glycosylation. In contrast, the effects of TM on the 
synthesis and glycosylation of the two SARS-CoV-E 
glycoproteins have permitted tentative assignment of 
functions to these proteins [14].
The Glycosylation of Coronavirus S 
Protein
Since the 1980s, the N-linked glycosylation S 
protein of coronavirus was defined for hepatitis virus 
MHV. S protein in the rough ER was found to acquire 
high mannose oligosaccharides. It has been found 
that the Golgi transport blocker (monensin) inhibited 
the transport of S protein from trans-Golgi network to 
the cell surface [15]. Other studies revealed that MHV 
S protein also modified the N-linked glycosylation 
of bovine coronavirus BCoV, alpha-coronavirus 
transmissible gastroenteritis virus (TGEV), and 
gamma-coronavirus infectious bronchitis virus (IBV). 
The high mannose oligosaccharides of SARS-CoV S 
protein were trimerized as early as 30 min post-entry 
into ER, before the acquisition of complex glycans in 
the Golgi apparatus using pulse-chase experiments 
coupled with fractionation. Then, the maturation 
status of S protein can be monitored by its sensitivity 
to endoglycosidase H. This enzyme hydrolyzes the 
high mannose glycans [16]. After that, the structure 
of N-linked glycosylation of S protein was determined 
using mass spectrometry. This linked was enriched 
with high mannose, hybrid and complex glycans with 
Figure 1: The structure of tunicamycin drugbank
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or without bisecting N-acetyl-galactosamine (GalNAc), 
and core fucose. A 12 out of 23 putative glycosylation 
sites detected of SARS-CoV S protein were actually 
glycosylated [17].
The SARS-CoV S protein has two domains 
S1 and S2. When the S1 domain of bovine-CoV S 
protein was cloned and expressed in insect cells, 
the mature S protein was glycosylated and bound 
by neutralizing monoclonal antibodies. On the other 
hand, the infected cells with TGEV in the presence 
of TM, the antigenicity of both S and M protein, were 
significantly reduced [18]. This may confirm that TM 
is an inhibitor factor of the glycosylation proteins. It 
has been demonstrated that the inhibition of N-linked 
glycosylation by TM or removal of N-linked glycans by 
PNGase F reduced TGEV-induced IFN-α production. 
Therefore, the N-linked glycans on SARS-CoV S 
protein may be a pathogen associated molecular 
pattern recognized by host pattern recognition 
receptors. These receptors are activated downstream 
antiviral innate immune response. The growth of 
coronavirus in the presence inhibitor TM resulted in 
the production of spikeless, non-infectious virions 
which were devoid of S protein [19], [20].
The Glycosylation of Coronavirus M 
Protein
M protein of coronaviruses is the most 
abundant protein comprising of 220–260 amino 
acids. It plays a central role of the viral assembly. M 
protein is a multipass transmembrane protein with a 
short N-terminal ectodomain, three hydrophobic TM 
domains, and a large C-terminal endodomain. O-linked 
glycosylation of the mouse hepatitis virus M protein 
was first revealed in 1981. It was noted that in the 
presence of TM, M protein was still normally produced 
and glycosylated, resulting in the formation of none 
infectious virions containing normal amounts of N and 
M protein, but lacking S completely [21], [22].
Distinct from the O-linked glycosylation 
perceived in the M protein of bovine-coronavirus BCoV, 
human-coronavirus HCoV-OC43, alpha-coronavirus 
TGEV, gamma-coronavirus IBV, and turkey enteric 
coronavirus is all modified by N-linked glycosylation. 
This linked of M protein is sensitive to endoglycosidase 
H and can be inhibited by TM. The N-linked glycosylation 
sites were mapped to N3 and N6 of IBV. M protein of 
betacoronaviruses in other lineages is also N-linked 
glycosylated [23]. For example, SARS-CoV M protein 
contains a single N-glycosylation site at N4. When 
transiently transfected as a C-terminally FLAG-tagged 
protein, SARS-CoV M protein was found to obtain high 
mannose N-glycans and was modified into complex 
N-glycans in the Golgi. Although the glycosylation of the 
coronavirus M protein is a strongly conserved feature, 
this glycosylation is not important for virus assembly or 
replication [24], [25].
The Glycosylation of Coronavirus Non-
structural Proteins nsp3 and nsp4
Some of the luminal domains of nsps 
coronaviruses proteins undergo N-linked glycosylation 
in the ER. For instance, MHV nsp3 is inserted into 
ER cotranslationally and glycosylated at N1525. 
Glycosylation of nsp4 was detected in IBV at N48 
residue while for the nsp4 of MHV, two glycosylation 
sites were predicted at N176 and N237 residues. Till 
now, no study supports that TM inhibits N-linked glycans 
either in nsp3 or nsp4 [26], [27], [28].
The Glycosylation of Coronavirus PTMs 
Proteins
Coronavirus genome encodes various 
accessory proteins called apart from the structural and 
non-structural proteins (PTMs), most of which share 
no homology to any known proteins. However, some 
of the PTMs accessory proteins are incorporated in 
mature virions, others have been concerned in the 
modulation of host immune response and in vivo 
pathogenesis. One of the PTM proteins is HE protein 
which is a part of beta-coronaviruses S protein. The 
HE protein of bovine CoV was also shown to be 
glycosylated when expressed using human adenovirus 
vector. Furthermore, HE protein of MHV was found to 
be modified by N-linked glycosylation and was inhibited 
by TM but not monensin. The importance of N-linked 
glycosylation of coronavirus HE protein has not been 
fully characterized [14], [29].
The O-linked glycosylation of SARS-CoV 
3a protein and M shares the same N-exo/C-endo 
membrane topology. The both proteins contain three 
TM domains. O-linked glycans of the SARS-CoV 
protein 3a are resistant to the treatment of PNGase F, 
and pulse-chase analysis suggested that the 
oligosaccharides were acquired post-translationally. 
Protein 3a has been implicated in modulating host 
immune response [30], [31].
The sgRNA8 of SARS-CoV encodes a single 
protein 8ab. A 29-nt deletion in the center split open 
reading frame ORF8 into two smaller frames, encoding 
proteins 8a and 8b, respectively. The 8ab protein is 
cotranslationally smuggled into the ER and is N-linked 
glycosylated at N81. The 8b protein is synthesized in 
the cytosol and not modified. Both proteins 8b and 8ab 
were shown to interact and modified by ubiquitination. 
The glycosylation at N81 stabilized 8ab protein and 
protected it from proteasomal degradation. Protein 
8b is unstable and undergoes rapid proteasomal 
degradation. The ubiquitinated 8b and 8ab may mediate 
rapid degradation of IRF3 and regulate host antiviral 
innate immunity. The inhibition N-linked glycosylation 
of SARS-CoV 8ab protein by TM is not completely 
understood [32], [33].
T1 - Thematic Issue “Coronavirus Disease (COVID-19)” Microbiology
132 https://www.id-press.eu/mjms/index
Conclusions
The transmembrane structural proteins S, 
E, M, nsp3, nsp4, and accessory proteins (HE, 3a, 
and 8ab) of the most coronavirus family are modified 
by glycosylation. Although the M proteins of beta-
coronavirus adopt the special O-linked glycosylation, 
the M proteins of the other coronaviruses are modified 
by N-linked glycosylation. It has been registered that 
glycosylation of coronavirus S protein is essentially 
N-linked. The folding and intracellular trafficking N-linked 
glycans of the coronavirus S protein also constitute a 
significant part of conformation of mature protein. TM 
inhibits formation of the coronavirus E2 glycoprotein 
but does not prevent synthesis or glycosylation of the 
glycoprotein El. The antigenicity of TGEV S and M 
protein was significantly reduced in the presence of 
TM. M protein of the most Coronaviridae is sensitive to 
endoglycosidase H and can be inhibited by TM. Lack 
information about the effect TM on SARS-CoV N-linked 
glycans ns3 and ns4. HE and 8ab proteins of SARS-CoV 
glycosylation are inhibited by TM. Although TM inhibits 
N-linked glycosylation of coronaviruses glycoproteins, 
no drug available to inhibit O-linked glycosylation has 
been identified yet.
We concluded that TM inhibits E2, S, and M 
glycoproteins of coronaviruses. TM is also diminished 
glycosylation of PTMs such as HE and 8ab of SARS-CoV. 
Since TM has long been used as an anticancer and has 
the ability to inhibit glycoproteins of coronaviruses, we 
recommend to use this drug to treat the SARS-CoV-2.
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